Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial

Amaria, Rodabe N, Prieto, Peter A, Tetzlaff, Michael T · The Lancet Oncology · 2018